Case Reports in Otolaryngology
Volume 2019 (2019), Article ID 7126043, 6 pages
https://doi.org/10.1155/2019/7126043

Case Report

Bilateral Facial Paralysis and Deafness in a Child Treated for Acute Lymphoblastic Leukemia

Rafael V. Lucena, Yuri C. F. Fernandes, Débora B. Pazinatto, and Rebecca C. K. Maunsell

Department of Otolaryngology Head and Neck, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil

Correspondence should be addressed to Rafael V. Lucena; rafael_vicente@live.com

Received 22 March 2019; Accepted 14 October 2019; Published 6 November 2019

Academic Editor: Gabriella Cadoni

Copyright © 2019 Rafael V. Lucena et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Involvement of the ear and temporal bone in acute leukemias are uncommon. We report a case of atypical mastoiditis with bilateral facial paralysis in a child diagnosed with Acute Lymphoblastic Leukemia (ALL). A 20-month-old male child was diagnosed with ALL and developed otorrhea unresponsive to antimicrobial treatment during the first week of chemotherapy followed by hearing loss, loss of balance, and bilateral facial paralysis. A CT scan of the mastoids showed cortical erosion of the temporal bone and presence of soft tissue contents filling the mastoid cells and external auditory canal bilaterally. Mastoidectomy was performed to collect material for analysis. Histopathologic examination of the material revealed an active chronic inflammatory process, with a moderate amount of plasma cells. Chemotherapy was reintroduced 3 weeks after the surgical procedure, and progressive improvement of otorrhea and imbalance was noted. Grade III House–Brackmann peripheral facial paralysis persisted on 6-month follow-up, and the patient is in rehabilitation program.

1. Background

Acute lymphoblastic leukemia (ALL) accounts for 30% of all childhood malignancies. It involves malignant transformation and proliferation of immature lymphoid cells in the bone marrow, blood, or extramedullary sites [1]. Approximately 60% of cases occur in people under 20 years of age, with a peak between 2 and 5 years of age [2]. The WHO 2016 review establishes two major subtypes of the disease: B-cell acute lymphoblastic leukemia/lymphoma (most common) and T-cell acute lymphoblastic leukemia/lymphoma [3]. Clinical and laboratory presentation at diagnosis as well as genetic and biological aspects of leukemia cells are used as the main prognostic factors [4].

Involvement of the ear and temporal bone in acute leukemias is uncommon and may present as skin lesions, changes in the tympanic membrane, effusions in the middle ear, otitis media, hearing loss, or mastoiditis. Pathophysiology may be due to bleeding, leukemic infiltration, or opportunistic infection at these sites [5, 6]. Facial paralysis due to VII cranial pair involvement is very rare, with few cases described in the literature.

We report a case of atypical mastoiditis with bilateral peripheral facial paralysis in a child diagnosed with ALL.

2. Case Presentation

A 20-month-old male child was admitted to the emergency room with fever, associated with cutaneous-mucosal pallor, inappetence, irritability, and bruises in the lower limbs at the onset 11 days ago. He did not present any otological complaint, loss of balance, or signs of central nervous system involvement.

Laboratory analysis showed a white blood cell count of 79,300 × 10⁹/L with a differential of 8% lymphocytes and 92% blasts; hemoglobin was 7.9 g/dL, and platelet count was 79,000 × 10⁹/L. The patient referred to children’s hospital for complementary exams. The myelogram revealed acute lymphoid leukemia (ALL), with 98% of lymphoblasts. Immunophenotyping was compatible with CD10 + cytoplasmic IgM + B-cell precursor acute lymphoblastic leukemia (pre-B ALL), karyotype 45, XY, -21. Cerebrospinal fluid (CSF) analysis did not show the presence of leukemic cells, and a computed tomography (CT) scan of the head at that time showed no cranial abnormality.

Chemotherapy treatment was initiated with the AIEOP-BFM 2009 protocol: prednisone, daunorrubicin, vincristin, peg-asparaginase, and intrathecal methotrexate [7]. On the 11th day of treatment, serosanguineous otorrhea was initiated first in the right ear and after two days in the left ear. On the 19th day of treatment, the patient presented fever. The hemoglobin was 6.2 mg/dL, platelets 4,000/dL, and white blood cell count was 750/dL. Blood and secretions from the middle ear were cultured, and both were positive for Pseudomonas sp. A new CSF analysis was performed and found a white blood cell count of 7/mm³ without leukemic cells, low glucose concentration, or increased protein. Meropenem and otological drops of ciprofloxacin were introduced.

Although fever resolved, the patient maintained serosanguineous otorrhea. On the 27th day of chemotherapy, the parents reported that the child was unable to smile or locate sounds, besides presenting difficulties walking. The patient was then referred to otorhinolaryngology. Otoscopy showed bilateral purulent otorrhea and an opacified, apparently bulging, tympanic membrane bilaterally. There was no spontaneous or semispontaneous nystagmus, but the child was unable to walk without support. Severe facial mimic dysfunction was noted bilaterally (House–Brackmann grade IV), with no other cranial nerve impairment. A complete blood count revealed a hemoglobin level of 6.9 mg/dL, platelet count of 286,000/dL, and white blood cell count of 15,890/dL with 56% of polymorphonuclear leukopcytes, 28% of lymphocytes, and 15% of monocytes.

A CT scan of the ear and mastoids showed bone erosion of the temporal bone and mastoid and presence of soft tissue contents filling the mastoid cells, involving the ossicular chain with extension to the external auditory canal in both ears (Figures 1 and 2).

Figure 1: Cortical erosion of the temporal bone (yellow arrows) in a CT scan. 3D view.

Figure 2: Cortical erosion of the temporal bone (yellow arrows) in a CT scan. Axial view.

A right mastoidectomy and left tympanotomy were performed and a whitish fibroelastic friable lesion was found both in the mastoid extending to the tip of the mastoid and the middle ear with partial erosion of the posterior wall of the external ear canal. Large tympanic perforations were seen bilaterally with “hyperplasic” lesion filling the middle ear. The cortical part of the temporal bone and the underlying tissues were infiltrated in appearance (Figures 3–5). Histopathologic examination of the material revealed an active chronic inflammatory process, with a moderate amount of plasma cells and absence of blast cells.

Figure 3: Micro-otoscopy showing fibroelastic tissue in the external auditory canal.

Figure 4: Mastoidectomy showing erosion of the cortical bone.

Figure 5: Tissue of infiltrative aspect in the temporal bone.

The patient restarted chemotherapy after 3 weeks of the surgical procedure and progressively improved of balance complaints and otorrhea.

3. Outcome and Follow-Up

At 2-month follow-up Brainstem Evoked Response Audiometry (BERA) with click and tone burst stimulation revealed severe bilateral sensorineural hearing loss with absence of response in 90 dB in both ears (Figure 6).

Figure 6: Absence of response on BERA at 90 dB.

At a 6-month follow-up, the patient was in the maintenance phase of chemotherapy and presented mild improvement of the facial paralysis on the left side (grade III House–Brackmann). A new CT scan of the ears and mastoid showed no ossicular chain bilaterally, with apparent content of soft parts in the mastoid cells. He was referred to auditory rehabilitation program, but use of hearing aids has not shown recognizable improvement. No central nervous involvement of ALL has been identified.

4. Discussion

In the pioneer study by Druss in 1945, it was observed that patients with leukemia had a significant number of secondary otologic complications. He reviewed the medical records of 148 patients with different apresentations of leukemia and found that almost 17% experienced secondary complications such as hearing loss, nystagmus, vertigo, facial paralysis, and tympanomastoid infections [8].

In 1973, Paparella et al. conducted the first large study with temporal bones of leukemia patients. The authors analyzed 45 temporal bones of 25 patients with chronic and acute leukemia. They found that all clinical otologic problems occurred only in patients with acute form of leukemia, particularly in acute lymphocytic leukemia. The histopathological findings were leukemic infiltration, hemorrhage, and infection in middle ear more frequently than inner ear or external auditory canal [9].

Okura and Kaga in 1994 also described the histopathological findings of the middle ear in 19 patients with leukemia. He observed middle ear effusion in 8 of 35 ears analyzed, and in 4 of these ears effusion floating tumor cells were found. The study suggests that the major causes of middle ear effusion in patients with leukemia are infection related to immunological deficiency, obstruction of the Eustachian tube with infiltration of tumor cells, and a tendency to bleed due to hematological problems [10].

In our case, bilateral serosanguineous otorrhea associated with fever initially led to the suspicion of suppurative acute otitis media. Signs of an active bacterial infection with pus and local inflammatory reaction were not present at this time probably due to the absence of polymorphonuclear cells caused by leukemia and chemotherapy. The change in the aspect of otorrhea is associated with its maintenance even during treatment with antibiotic therapy and the appearance of other symptoms such as loss of balance and facial paralysis alerted to an atypical presentation of mastoiditis. Pediatric acute mastoiditis of noninfectious etiology is much rarer than true infectious mastoiditis. It should be suspected in every atypical, persistent, or recurrent case of acute mastoiditis [11]. According to Kontorinis, all cases of atypical mastoiditis must be conducted with routine laboratory investigation, imaging studies, and tissue biopsies.

The case presented by Todd and Bowman raises questions regarding the role, timing, and extent of surgery in atypical acute mastoiditis in leukemia patients. According to the author, surgery is appropriate when the patient’s course indicates more bacteriologic and pathologic information is needed. When tumor is encountered in the ear and intraoperative histopathologic study is inconclusive or not available, the extent of surgery must be limited to obtaining sufficient tissue for histopathologic diagnosis, reducing tumor bulk (to facilitate the subsequent usefulness of radiation or chemotherapy) and preserving function of the ear [5]. In the present case, exploratory mastoidectomy was performed in the right ear to collect material and posterior decision-making considering the patient’s underlying disease. Microscopy of the left ear revealed a lesion with similar and particularly atypical aspect for infectious otomastoiditis, and again the decision was to collect biopsy specimen only. As described in the literature, since diagnosis was not clear, the decision was not to decompress the facial nerve at the time [5].

Bilateral facial paralysis and profound sensorineural hearing loss presented by the patient may have occurred due to the facial and acoustic nerve involvement by leukemic infiltration or severe local inflammatory reaction triggered or not by infection. Bilateral facial paralysis is an unusual clinical entity that occurs in less than 1% of patients with facial paralysis. Bilateral facial paralysis is even more rare in children, and establishing its etiology can be challenging [12]. The case reports about acute lymphoblastic leukemia suggest a preponderance of T-cell leukemia for this complication [13]. Neurologic symptoms and meningeal signs should always be carefully investigated as 50% of leukemia children with central nervous system relapse can present with cranial nerve involvement, particularly of the facial nerve [12]. There are at least two possible explanations for the association of facial paralysis and leukemia: a direct infiltration of the nerve with leukemic cells and a common etiologic infectious factor such as Epstein–Barr virus or human T-cell lymphotropic virus. Neuropathy occurs due to compression and damage of the nerve and their vessels by infiltration of leukemic cells [14]. Although the histopathological analysis was not conclusive for leukemic infiltration of the mastoid, other multiple factors are probably associated in this case [15], such as local infection exacerbated by the depressed immune status, drug toxicity, hemorrhage, and local edema, making it very difficult to separate and define a single etiollogy. Partial improvement of facial paralysis in response to chemotherapy leads us to hypothesize that perineural infiltration may have occurred.

A database search of Medline, PubMed, BVS-BIREME, Web of Science, Embase, and SCOPUS, from 1984 to December 2018, was performed for studies that reported facial paralysis in child population with acute lymphoblastic or myeloid leukemia. The search terms used in database searches were “Facial Paralysis” AND “Precursor Cell Lymphoblastic Leukemia-Lymphoma” OR “Acute Myeloid Leukemia” AND “Infant” OR “Preschool” OR “Child” OR “Adolescent”. We found five case reports of children or adolescents with acute lymphoblastic leukemia presenting with bilateral facial paralysis. Two cases [14, 16] had bilateral facial paralysis as a first symptom of leukemic relapse in the central nervous system (CNS), and involvement of the middle ear with otological symptoms was present in only one. The chemotherapy treatment showed no improvement in both cases. Krishnamurthy et al. [17] reported a case of an infant with bilateral facial paralysis and ALL. He had performed bilateral tympanocentesis after a CT scan showing presumed bilateral mastoiditis unresponsive to antibiotics. Chemotherapy was initiated, and facial paralysis improved at a 6-month follow-up. Berger et al. [18] reported a case of an 8-year-old boy who presented otalgia and was unsuccessfully treated for otitis media. He presented a soft tissue edema with severe stenosis of bilateral external auditory canal and developed a bilateral facial paralysis House–Brackman grade VI. Similarly, to the present case, a CT scan of the temporal bone revealed opacification of the external ear canal and mastoid. His audiogram presented a mild conductive hearing loss. Further investigation led to B-cell ALL diagnosis. Different from ours, no biopsy was performed, and the patient’s left side facial paralysis improved after 1 month of chemotherapy.

A concise review of the literature is presented in Table 1.

Table 1: Literature review.

Study, year
No. of patients
Age of patients
Disease
Facial paralysis (FP) side
Otological surgery
Middle ear biopsy
Outcome of FP with chemotherapy

Todd and Bowman, 1984 [5]
1
13 yr
AML
Right
Yes
Granulocytic sarcoma
Complete resolution 6-month follow-up

Levy et al., 1986 [15]
1
5
AML
Right
Yes
Leukemic infiltration
Complete resolution

Ingram, 1990
9
ND
ALL
ND
No
—
ND

Zappia et al., 1990 [19]
1
6 yr
AML
Left
Yes
Granulocytic sarcoma
Complete resolution in 3-month follow-up

Juhn and Inoue, 1996 [20]
1
14 yr
T-cell ALL
Bilateral (alternately)
No
No
ND

Eser et al., 2001 [21]
1
14 yr
AML
AML
No
No
Complete resolution

Buyukavci et al., 2002 [13]
1
13 yr
T-cell ALL
Bilateral
No
No
Partial resolution

Krishnamurthy et al., 2002 [17]
1
11 mo
ALL
Bilateral
Yes
No
Improvement in 6-month follow-up

1
11 mo
AML
Right
No
No
No improvement

1
6 yr
ALL (Burkitt’s)
Left
No
No
Improvement in 6-month follow-up

Antunes et al., 2004 [16]
1
18 yr
ALL
Bilateral
No
No
No improvement

Bilavsky, 2006
1
8 mo
AML
Right
No
No
ND

Lakhotia et al., 2015 [14]
1
15 yr
Pre-B-cell ALL
Bilateral
No
No
No improvement

Li et al., 2016 [22]
1
11 yr
T-cell LBL
Right
Yes
Lymphoma
Complete resolution

Berger et al., 2016 [18]
1
8 yr
B-cell ALL
Bilateral
Yes
No
Partial resolution

Young et al., 2016 [23]
1
2 yr
AML
Bilateral
No
No
Improvement in 5-month follow-up

Chiang et al., 2017 [24]
1
12 yr
T-cell ALL
Right
No
No
Complete resolution

Sagar et al., 2018 [25]
1
6 yr
AML
Right
Yes
Leukemic infiltration
Complete resolution

Abbreviations: ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, LBL: lymphoblastic lymphoma, ND: no description.

5. Learning Points

The patient discussed in this study presented unusual symptoms rarely and diversely reported in the literature. The involvement of the temporal bone in acute leukemias in children, although rare, should always be remembered either as initial symptomatology or during the course of chemotherapy when apparently major inflammatory response associated or not to infection may result in complications. Patients who present atypical mastoiditis, symptoms of imbalance or facial paralysis (uni- or bilateral) should be referred to the otorhinolaryngologist. A broad investigation and active discussion amongst the treating oncologist and otolaryngologist, with laboratory tests, imaging exams, and if necessary surgical intervention, are necessary in order to establish a diagnosis and provide the best treatment.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

T. Terwilliger and M. Abdul-Hay, “Acute lymphoblastic leukemia: a comprehensive review and 2017 update,” Blood Cancer Journal, vol. 7, no. 6, p. e577, 2017.

H. Inaba, M. Greaves, and C. G. Mullighan, “Acute lymphoblastic leukaemia,” The Lancet, vol. 381, no. 9881, pp. 1943–1955, 2013.

D. A. Arber, A. Orazi, R. Hasserjian et al., “The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia,” Blood, vol. 127, no. 20, pp. 2391–2405, 2016.

S. P. Hunger and C. G. Mullighan, “Acute lymphoblastic leukemia in children,” New England Journal of Medicine, vol. 373, no. 16, pp. 1541–1552, 2015.

N. W. Todd and C. A. Bowman, “Acute myelogenous leukemia presenting as atypical mastoiditis with facial paralysis,” International Journal of Pediatric Otorhinolaryngology, vol. 7, no. 2, pp. 173–177, 1984.

G. Almadori, M. Del Ninno, G. Cadoni, A. Di Mario, and F. Ottaviani, “Facial nerve paralysis in acute otomastoiditis as presenting symptom of FAB M2, T8;21 leukemic relapse. Case report and review of the literature,” International Journal of Pediatric Otorhinolaryngology, vol. 36, no. 1, pp. 45–52, 1996.

V. Conter, M. G. Valsecchi, B. Buldini et al., “Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis,” The Lancet Haematology, vol. 3, no. 2, pp. e80–e86, 2016.

J. G. Druss, “Aural manifestations of leukemia,” Archives of Otolaryngology, vol. 42, no. 4, pp. 267–274, 1945.

M. M. Paparella, N. T. Berlinger, M. Oda, and F. El Fiky, “Otological manifestations of leukemia,” The Laryngoscope, vol. 83, no. 9, pp. 1510–1526, 1973.

S.-I. Okura and K. Kaga, “Temporal bone pathology of leukemia and malignant lymphoma with middle ear effusion,” Auris Nasus Larynx, vol. 21, no. 1, pp. 1–7, 1994.

G. Kontorinis, I. Psarommatis, C. Karabinos, Z. Iliodromiti, and M. Tsakanikos, “Incidence of non-infectious “acute mastoiditis” in children,” The Journal of Laryngology & Otology, vol. 126, no. 3, pp. 244–248, 2012.

V. Smith and D. N. Traquina, “Pediatric bilateral facial paralysis,” The Laryngoscope, vol. 108, no. 4, pp. 519–523, 1998.

M. Buyukavci, H. Tan, and R. Akdag, “An alarming sign for serious diseases in children: bilateral facial paralysis,” Pediatric Neurology, vol. 27, no. 4, pp. 312-313, 2002.

M. Lakhotia, H. R. Pahadiya, H. Kumar, J. Singh, G. R. Prajapati, and J. R. Sangappa, “Bilateral Facial Palsy a rare presenting symptom of acute lymphoblastic leukemia with CNS and BM Relapses,” Journal of Neurosciences in Rural Practice, vol. 6, no. 4, pp. 630–632, 2015.

R. Levy, G. Har-El, K. Segal, and J. Sidi, “Acute myelogenous leukemia presenting as facial nerve palsy. A case report,” International Journal of Pediatric Otorhinolaryngology, vol. 12, no. 1, pp. 49–53, 1986.

M. L. Antunes, M. C. M. Soares, A. O. Vicente, J. R. G. Testa, and Y. Fukuda, “Paralisia facial periférica bilateral na leucemia linfóide aguda: relato de caso,” Revista Brasileira de Otorrinolaringologia, vol. 70, no. 2, pp. 261–264, 2004.

S. N. Krishnamurthy, A. L. Weinstock, S. H. Smith, and P. K. Duffner, “Facial palsy, an unusual presenting feature of childhood leukemia,” Pediatric Neurology, vol. 27, no. 1, pp. 68–70, 2002.

M. H. Berger, S. Chen, C. Sidani, and R. Younis, “Bilateral facial paralysis as presenting symptoms in acute lymphoblastic leukemia,” Otology & Neurotology, vol. 37, no. 10, pp. e412–e413, 2016.

J. J. Zappia, F. A. Bunge, C. F. Koopmann, and K. D. McClatchey, “Facial nerve paresis as the presenting symptom of leukemia,” International Journal of Pediatric Otorhinolaryngology, vol. 19, no. 3, pp. 259–264, 1990.

Y. J. Juhn and S. Inoue, “Facial nerve palsy as an early manifestation of relapse in T-cell acute lymphoblastic leukemia,” Ear, Nose & Throat Journal, vol. 75, no. 3, pp. 157–160, 1996.

B. Eser, M. Cetin, O. Kontas et al., “Facial nerve paralysis and paraplegia as presenting symptoms of acute myeloid leukemia,” Japanese Journal of Clinical Oncology, vol. 31, no. 2, pp. 86–88, 2001.

B. Li, S. Liu, H. Yang, and W. Wang, “Primary T-cell lymphoblastic lymphoma in the middle ear,” International Journal of Pediatric Otorhinolaryngology, vol. 82, pp. 19–22, 2016.

C. W. Young, C. S. Ho, N. C. Chiu et al., “Acute myeloid leukemia with initial presentation of facial palsy and exophthalmos,” Acta Neurologica Taiwanica, vol. 25, pp. 18–20, 2016.

L. Y. Chiang, J. R. Crawford, and D. J. Kuo, “Unilateral facial nerve palsy as an early presenting symptom of relapse in a paediatric patient with acute lymphoblastic leukaemia,” BMJ Case Reports, vol. 2017, Article ID bcr2017219501, 2017.

P. Sagar, S. Budhiraja, M. Rajeshwari, and R. Kumar, “Rare initial presentation of acute myeloid leukemia as facial palsy,” Indian Journal of Medical and Paediatric Oncology, vol. 39, no. 4, p. 555, 2018.